We are international
Donate
TEXT SIZE   


Global Advances in Myeloma:
Providing Best Options for Treatment in 2015

Join us for a provocative program format that includes “point and counterpoint” presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma.

Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma. 

Friday Satellite Symposium preceding the 57th ASH Annual Meeting.

 

10.19.15

click on the image above to watch the teleconference
(to view the teleconference in fullscreen, click on the bottom right square icon beside the YouTube logo)

Event Slides:

Debate 1: Will New Diagnostic Criteria and Early Treatment Improve Survival or Result in More Aggressive Disease at Relapse?
Debate 2: Should Risk-Adapted Therapy Be Used for Patients With Newly Diagnosed MM?
Debate 3: Should MRD Be Used to Guide Treatment Decisions Regarding Maintenance Therapy?
Debate 4: Are Emerging Systemic Therapies Best in Patients With Newly Diagnosed or Relapsed MM?
 

Hyatt Regency Orlando
Registration and Lunch Room: Regency R
Symposium Room: Regency S
9801 International Drive
Orlando, FL 32819
  Friday, December 4, 2015 (EST)
12:00 PM - 12:30 PM Registration
12:30 PM - 3:00 PM Symposium
9:30 AM PST / 10:30 AM MST / 11:30 AM CST
(Event will be livestreamed)

Format and Topics:

This symposium will use a provocative and informative point-counterpoint format to provide multiple perspectives on evolving data, guideline changes, and expert recommendations for optimal management of patients with multiple myeloma (MM).

In this format, international experts will debate and discuss how recent updates and practice changes affect therapeutic decisions faced by clinicians treating myeloma in the frontline and relapsed settings in 2015 and beyond.

Symposium Topics Are:

  • Benefits and risks associated with new diagnostic criteria and early treatment of MM
  • Risk-adapted therapy for patients with newly diagnosed MM
  • Using minimal residual disease to guide maintenance therapy
  • Emerging systemic therapies for newly diagnosed MM or with relapsed disease     
 

Faculty: 


Brian G.M. Durie, MD (Program Director)
Institution: Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, USA 

Shaji Kumar, MD
Institution: Mayo Clinic, Rochester, Minnesota, USA 

Philippe Moreau, MD 
Institution: University Hospital of Nantes, Nantes, France 

Bruno Paiva, PhD 
Institution: University of Navarra, Pamplona, Spain 

Antonio Palumbo, MD 
Institution: University of Turin, Turin, Italy 

Jesus F. San Miguel, MD, PhD 
Institution: University of Navarra, Pamplona, Spain

Learning Objectives
At the conclusion of the activity, participants should be able to:
  • Initiate therapy at the appropriate disease stage based on current evidence-based recommendations and multiple myeloma diagnosis criteria
  • Choose optimal treatment strategies for patients with newly diagnosed multiple myeloma
  • Use appropriate maintenance therapy approaches for multiple myeloma to maximize patient outcomes
  • Select optimal salvage therapies for patients with relapsed/refractory multiple myeloma based on available data, current guidelines, and expert recommendations
  • Implement use of newly emerging treatment options into clinical practice as new data, approvals, or indications become available

Accreditation Statement 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians. 

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. 

This program is sponsored by the Annenberg Center for Health Sciences at Eisenhower, Clinical Care Options, and the International Myeloma Foundation and supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, Takeda Oncology and The Binding Site.

Americans With Disabilities Act: 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Allison Hughes prior to the live event at ahughes@pimed.com.


 related articles